期刊文献+

硼酸盐缓冲液制备尿酸酶复合脂质体及尿酸酶的特性 被引量:1

Preparation and characterization of uricase in uricase-catalase liposomes prepared using borate buffer
下载PDF
导出
摘要 目的研究硼酸-硼砂缓冲液制备的尿酸酶-过氧化氢酶脂质体(BUCLP)中尿酸酶的体外特性。方法采用逆向蒸发法制备BUCLP,并考察其部分理化性质特性。结果 BUCLP中尿酸酶最适温度保持在40℃,最适p H值由8.5降为8.0,而Km值也由14.207μmol/L降为13.623μmol/L;尿酸酶-过氧化氢酶(UAC)与空白纳米脂质体作用后,再与FITC结合,其荧光强度高于游离UAC与FITC结合的荧光强度,且BUCLP在280 nm处的荧光强度高于游离UAC。结论尿酸酶和过氧化氢酶联合制备成BUCLP后尿酸酶的活性增加。 Objective To characterize the property of uricase loaded in uricase-catalase liposomes (BUCLPs) prepared using borate buffer. Methods BUCLPs were prepared using reverse-phase evaporation, and the physicochemical properties of uricase in the prepared BUCLPs were examined. Results The optimal temperature of BUCLP and URI was 40 ℃, their optimal pH values were 8.0 and 8.5, and their Michaelis-Menten constants were 14.207 μmol/L and 13.623 μmol/L, respectively. Fluorescence intensity of nanoliposome-loaded uricase-catalase that bound to FITC was higher than that of uricase-catalase binding directly with FITC; the fluorescence intensity of BUCLP was higher than that of free uricase-catalase at 280 nm. Conclusion Uricase activity is enhanced after loading in uricase and catalase liposomes.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2015年第2期268-271,共4页 Journal of Southern Medical University
基金 国家自然科学基金(30973645)~~
关键词 尿酸酶 过氧化氢酶 脂质体 米氏常数 荧光图谱 uricase catalase liposomes michaelis-menten constand fluorescence spectrum
  • 相关文献

参考文献10

  • 1Krishnan E, Kwoh CK, Schumacher HR, et al.Hyperuricemia andincidence of hypertension among men without metabolic syndrome[J].Hypertension, 2007, 49(2):298-303.
  • 2Sakai H, Tsutamoto T, Tsutsui T, et al.Sermn level of uric acid,partly secreted from the failing heart is a prognostic marker inpatients with congestive hean failure[J].Circ J, 2006, 70(1):1006-11.
  • 3Roddy E, Doherty M.Treatment of hyperuricaemia and gout[J].Clin Med (Northfield Il), 2013, 13(4):400-3.
  • 4王娜,赵春景,黄开顺,滕永真,张景勍.产朊假丝酵母尿酸酶脂质纳米粒的制备及其药效学特性分析[J].中国生物制品学杂志,2013,26(8):1147-1150. 被引量:15
  • 5陈焱,黄健花,蔡春明,王兴国.过氧化氢酶固体脂质纳米粒的制备[J].食品与生物技术学报,2011,30(4):489-494. 被引量:4
  • 6Yoshimoto M, Miyazaki Y, Kudo Y, et al.Glucose oxidationcatalyzed by liposomal glucose oxidase in the presence of catalasecontainingliposomes[J].Biotechnol Prog, 2006, 22(3):704-9.
  • 7Tan QY, Zhang JQ, Wang N, et al.Improved biological propertiesand hypouricemic effects of uricase from Candida utilis loaded innovel alkaline enzymosomes[J].Int J Nanomed, 2012, 7:3929-38.
  • 8Tan QY, Zhang JL, Wang N, et al.Uricase from Bacillus fastidiousloaded in alkaline enzymosomes:Enhanced biochemical andpharmacological characteristics in hypouricemic rats[J].Eur JPharm Biopharm, 2012, 82(1):43-8.
  • 9Tan QY, Wang N, Yang H, et al.Characterization, stabilization andactivity of uricase loaded in lipid vesicles[J].Int J Pharm, 2010, 384(1/2):165-72.
  • 10Qiu YZ, Huang ZH, Song FJ.Enzymatic activity enhancement ofNon-Covalent modified superoxide dismutase and moleculardocking analysis[J].Molecules, 2012, 17(4):3945-56.

二级参考文献20

  • 1刘冰,梁婵娟.生物过氧化氢酶研究进展[J].中国农学通报,2005,21(5):223-224. 被引量:128
  • 2孟尧,辛渝,谭晓晶,许晓燕,余彩霞,杨波,孟延发.朊圆酵母尿酸酶的基本特性研究[J].四川大学学报(自然科学版),2006,43(2):414-419. 被引量:6
  • 3M. Garcia-Fuentes. Design of lipid nanopartieles for the oral delivery of hydrophilie macromolecules[J]. Colloids and Sur- faces B: Biointerfaces,2002 (27) : 159-168.
  • 4B Gander, E Wehrl, R Alder. Quality improvement of spray-dried, protein-loaded D,L-PLA micro-spheres by appropri- ate polymer solvent selection[J]. Mi-eroencapsulation, 1995 (12): 83 - 97.
  • 5XIE Shu-yu, WANG Si-liang, ZHOU Wen-zhong,et al. Effect of PLGA as a polymeric emulsifier on preparation of hy- drophilic protein-loaded solid lipid nanoparticles[J]. Colloids and Surfaces B: Biointerfaees, 67 (2008) 199- 204.
  • 6Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: Influence of the formulation and processing parameters[J]. European Journal of Pharmaceutical Sciences, 2006,27 ( 2 - 3) : 143 - 149.
  • 7LI Ya-ping, PEI Yuan-ying, GAO Xiu-jian,et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, prepara- tion and biodistribution in rats[J ]. Journal of Controlled Release, 2001,71 ( 2 ): 203 - 211.
  • 8Lucienne J. The targeted delivery of cancer drugs across the blood-brain barrier:chemical modifications of drugs or drug- nanoparticales[J]. Drug Discovery Today, 2008,13 ( 23 - 24 ) : 1099 - 1106.
  • 9Gulyaev AE, Gelperina SE,Skidan IN et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles[J]. Pharmaceutical Research, 1999,16(10) :1564- 1569.
  • 10Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase / xanthine-dehydrogenase inhibitor for the management of hype- ruricemia in adults with gout [J]. Clin Ther, 2009, 31 (11): 2503-2518.

共引文献15

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部